B of A Securities Upgrades Haemonetics to Buy, Raises Price Target to $80

Benzinga Newsdesk www.benzinga.com Positive 88.8%

Neg 0% Neu 0% Pos 88.8%

B of A Securities analyst Craig Bijou upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and raises the price target from $72 to $80.